Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.
Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology.
Nucleai has partnered with Sirona Dx to provide an integrated spatial proteomics solution for pharmaceutical and biotechnology businesses for drug development.
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer (ES-SCLC) and other neuroendocrine carcinomas (NECs).
Adcendo, a clinical-stage biotechnology company developing antibody-drug conjugates (ADCs) for cancer treatment, has raised $75m in a Series C funding round.
Eli Lilly and Company has agreed to acquire all outstanding shares of CrossBridge Bio for up to $300m in cash, comprising an upfront payment and a milestone payment tied to specified development progress.
Travere Therapeutics has received the US Food and Drug Administration (FDA) full approval for Filspari (sparsentan) to reduce proteinuria in adult and paediatric patients aged eight years and above with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.
Roche has signed a new collaboration agreement with C4 Therapeutics to jointly advance research in the field of degrader-antibody conjugates (DACs), aiming to introduce a new therapeutic modality for cancer.
Gan & Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea.
Everest Medicines’ wholly owned subsidiary EverSea Medicines (Singapore) has signed a share purchase agreement to conditionally acquire Hasten Biopharmaceuticals, a subsidiary of Hasten Biopharmaceuticals (Asia).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.